Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma
Evaluation of the safety and effectiveness of metformin as an adjunct to RCHOP chemotherapy for patients with newly diagnosed diffuse large-B cell lymphoma
Diffuse Large B Cell Lymphoma
DRUG: Metformin
Incidence of treatment-emergent adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 6 months|Response rates, Overall, partial and complete responses to chemoimmunotherapy, 6 months
Progression-free survival, Survival with freedom from progression, 2-5 years|Overall survival, Survival from diagnosis until death or last follow-up, 2-5 years|Event-free survival, Survival from diagnosis until death or progression, 2-5 years|Time to progression or relapse, Time from diagnosis until disease progression or relapse, 2-5 years
Patients with newly diagnosed diffuse large-B cell non Hodgkin lymphoma, irrespective of cell of origin status will receive metformin in combination to Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) chemotherapy for 6 cycles, until response evaluation as reported elsewhere:

1.- Rituximab 375 mg/m2 IV, day 1. 2.- Cyclophosphamide 750 mg/m2 IV, day 1. 3.- Doxorubicin 50 mg/m2 IV day 1. 4.- Vincristine 1.4 mg/m2 IV (2 mg maximum dose). 5.- Prednisone 60 mg/m2 PO days 1-5. Six cycles every 21 days.

Metformin will be added and administered in an outpatient basis, starting with 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, and lastly 850 mg every 8 hours maximum dose until re-staging. Laboratory tests will be performed serially.